FDA approves the Rybelsus to Ozempic tablets name change, orphaning an established search term

On February 4, 2026, the US Food and Drug Administration approved Ozempic as the proprietary name for Novo Nordisk's oral semaglutide tablets for adults with type 2 diabetes, in 1.5 mg, 4 mg and 9 mg strengths ^[3]. The active ingredient is the same semaglutide that has been sold as Rybelsus since 2019, so the change is effectively a rebrand of an existing medicine rather than a new drug ^[2].

The paperwork behind it is unusually plain. FDA's approval letter covers supplemental new drug application NDA 213051/S-030, filed June 23, 2025, and states that the supplement "provides for an update to the product labeling to change the name of the product from Rybelsus (formulation R2) to Ozempic (semaglutide) tablets" ^[1]. The letter is addressed to "Ozempic (semaglutide) tablets and Rybelsus (semaglutide) tablets" and was electronically signed on January 30, 2026 ^[1]. In other words, the official FDA labeling for this product still carries both names in one combined document, even as the marketing moves in one direction.

Two names, one medicine

The strengths do not line up one-for-one, which is the detail most likely to cause confusion. According to Novo's Michael Radin, M.D., executive director of diabetes medical affairs, the 3 mg, 7 mg and 14 mg doses of Rybelsus are equivalent, respectively, to the new 1.5 mg, 4 mg and 9 mg strengths of the Ozempic pill ^[4]. The new tablet is slightly smaller and uses a new coating, and the reformulation improved bioavailability so that lower milligram numbers deliver comparable efficacy and safety ^[4]. Reuters reported that FDA based the new doses on a bioequivalence study plus the existing Rybelsus clinical trial data ^[3].

Sources describe the strengths slightly differently. HCPLive's summary refers to "the FDA approval of 14 mg oral semaglutide now branded as Ozempic" ^[2], while Reuters and Fierce Pharma both describe the approved Ozempic tablet strengths as 1.5 mg, 4 mg and 9 mg ^[3][4]. The FDA letter itself does not list strengths in the text available here ^[1].

Novo has been explicit that the old name is going away in the US. "The Rybelsus brand won't be carried forward but the tablets will continue under the iconic brand of Ozempic," said Ed Cinca, senior vice president of marketing and patient solutions at Novo Nordisk ^[4]. The company said Rybelsus will be discontinued as a brand across the US, with Rybelsus branding continuing outside the country ^[4]. The campaign tagline is "There is only one Ozempic" ^[4].

The stated reason is recognition. "Because Ozempic is so well known, people often ask whether there's an oral option for people with type 2 diabetes, without realizing Rybelsus has been available since 2019," Cinca told Reuters ^[3].

Why it matters for patients

A brand name is also a search term, a pharmacy label, a prior authorization field and a savings-card lookup. For years, "Rybelsus" was the only way to ask about semaglutide in pill form for type 2 diabetes. Now that name points to a product Novo is retiring in the US ^[4], while pages and answers built around "Ozempic tablets" or "Ozempic pill" are newer and thinner. That mismatch can leave people reading older material about a name that no longer matches the box.

The dose mapping is the practical wrinkle: a person previously on 14 mg of Rybelsus would see 9 mg on an Ozempic tablet package, which Novo says is an equivalent dose, not a reduction ^[4]. Novo said current Rybelsus patients "should continue their medication as directed" but should "speak with their healthcare professionals about transitioning to the Ozempic pill, as appropriate" ^[4].

Exactly when Rybelsus-labeled stock stops reaching wholesalers and runs out at pharmacies is not specified in the sources reviewed here.

What happens next

Novo said the Ozempic pill would launch in the second quarter of 2026 ^[3], with the rollout officially starting Monday, May 4 ^[4]. The company plans to distribute through roughly 70,000 brick-and-mortar pharmacies plus its NovoCare pharmacy and certain telehealth providers ^[4]. A separate FDA decision on a 25 mg dose of Ozempic tablets is expected by the end of 2026 ^[3].